A detailed history of Goldman Sachs Group Inc transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 87,605 shares of INMB stock, worth $772,676. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,605
Holding current value
$772,676
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$10.53 - $14.01 $922,480 - $1.23 Million
87,605 New
87,605 $1.03 Million
Q1 2022

May 16, 2022

SELL
$6.42 - $11.39 $128,740 - $228,403
-20,053 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$9.97 - $20.38 $199,928 - $408,680
20,053 New
20,053 $205,000

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $158M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.